Bezafibrate treatment rescues neurodevelopmental and neurodegenerative defects in 3D cortical organoid model of MAPT frontotemporal dementia
Open Access
- 14 August 2025
- journal article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (8) , e70419
Abstract
INTRODUCTION: The intronic MAPT mutation IVS10+16 is linked to familial frontotemporal dementia, causing hyperphosphorylation and accumulation of tau protein, resulting in synaptic and neuronal loss and neuroinflammation in patients. This mutation disrupts MAPT gene splicing, increasing exon 10 inclusion and leading to an imbalance of 3R and 4R Tau isoforms.METHODS: We generated patterned cortical organoids from isogenic control and mutant human induced pluripotent stem cell (iPSC) lines. Nanostring gene expression analysis, immunofluorescence, and calcium imaging recordings were used to study the impact of the MAPT IVS10+16 mutation on neuronal development and function.RESULTS: Tau mutant cortical organoids showed altered mitochondrial function and gene expression related to neuronal development, with synaptic markers and neuronal activity reduction. Bezafibrate treatment restored mitochondrial content and rescued synaptic functionality and tau physiology.DISCUSSION: These findings suggest that targeting mitochondrial function with bezafibrate could potentially reverse tau‐induced neurodevelopmental deficits, highlighting its therapeutic potential for tauopathies like frontotemporal dementia.Highlights: The IVS 10+16 MAPT mutation significantly disrupts cortical differentiation and synaptic maturation, evidenced by downregulated genes associated with synapses and neuronal development. Tau‐mutant cortical organoids exhibit mitochondrial dysfunction, with fewer and smaller mitochondria alongside tau hyperphosphorylation and aggregation, which further contribute to neuronal damage and disease progression. Treatment with bezafibrate effectively normalizes mitochondrial parameters, enhances neuronal integrity and synaptic maturation, and restores network functionality, showcasing its promise as a therapeutic strategy for tauopathies. The 3D in vitro disease model used in this study proves valuable for studying tauopathies and testing new drugs, effectively mimicking key aspects of tau‐related neurodegeneration.Keywords
All Related Versions
Funding Information
- Regione Lazio (A0112E0073)
- Fondazione Telethon (GGP20037)
This publication has 70 references indexed in Scilit:
- 13 reasons why the brain is susceptible to oxidative stressRedox Biology, 2018
- Transgenic GDNF Positively Influences Proliferation, Differentiation, Maturation and Survival of Motor Neurons Produced from Mouse Embryonic Stem CellsFrontiers in Cellular Neuroscience, 2016
- Tau in physiology and pathologyNature Reviews Neuroscience, 2015
- A role for intracellular zinc in glioma alteration of neuronal chloride equilibriumCell Death & Disease, 2014
- Bezafibrate administration improves behavioral deficits and tau pathology in P301S miceHuman Molecular Genetics, 2012
- Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's diseaseHuman Molecular Genetics, 2011
- Clinical Aspects of Familial Forms of Frontotemporal Dementia Associated with ParkinsonismJournal of Molecular Neuroscience, 2011
- Anomalous levels of Cl − transporters in the hippocampal subiculum from temporal lobe epilepsy patients make GABA excitatoryProceedings of the National Academy of Sciences, 2006
- Distribution of the phosphorylated microtubule-associated protein tau in developing cortical neuronsNeuroscience, 1994
- In vivo phosphorylation sites in fetal and adult rat tau.Journal of Biological Chemistry, 1993